TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Nanjing Sanhome Pharmaceutical
US Patent
Nanjing Sanhome Pharmaceutical
US Patent
Affinity DataIC50: 1nMT: 2°CAssay Description:Serially diluting the compound of the present invention from 1 uM initial concentration in three-fold fashion and formulating 10 concentrations (50.8...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Nanjing Sanhome Pharmaceutical
US Patent
Nanjing Sanhome Pharmaceutical
US Patent
Affinity DataIC50: 2.12nMT: 2°CAssay Description:Serially diluting the compound of the present invention from 1 uM initial concentration in three-fold fashion and formulating 10 concentrations (50.8...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Nanjing Sanhome Pharmaceutical
US Patent
Nanjing Sanhome Pharmaceutical
US Patent
Affinity DataIC50: 2.28nMT: 2°CAssay Description:Serially diluting the compound of the present invention from 1 uM initial concentration in three-fold fashion and formulating 10 concentrations (50.8...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Nanjing Sanhome Pharmaceutical
US Patent
Nanjing Sanhome Pharmaceutical
US Patent
Affinity DataIC50: 6.45nMT: 2°CAssay Description:Serially diluting the compound of the present invention from 1 uM initial concentration in three-fold fashion and formulating 10 concentrations (50.8...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Nanjing Sanhome Pharmaceutical
US Patent
Nanjing Sanhome Pharmaceutical
US Patent
Affinity DataIC50: 6.81nMT: 2°CAssay Description:Serially diluting the compound of the present invention from 1 uM initial concentration in three-fold fashion and formulating 10 concentrations (50.8...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Nanjing Sanhome Pharmaceutical
US Patent
Nanjing Sanhome Pharmaceutical
US Patent
Affinity DataIC50: 39.4nMT: 2°CAssay Description:Serially diluting the compound of the present invention from 1 uM initial concentration in three-fold fashion and formulating 10 concentrations (50.8...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Nanjing Sanhome Pharmaceutical
US Patent
Nanjing Sanhome Pharmaceutical
US Patent
Affinity DataIC50: 57.9nMT: 2°CAssay Description:Serially diluting the compound of the present invention from 1 uM initial concentration in three-fold fashion and formulating 10 concentrations (50.8...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1 [T315I](Homo sapiens (Human))
Nanjing Sanhome Pharmaceutical
US Patent
Nanjing Sanhome Pharmaceutical
US Patent
Affinity DataIC50: >1.00E+3nMT: 2°CAssay Description:Serially diluting the compound of the present invention from 1 uM initial concentration in three-fold fashion and formulating 10 concentrations (50.8...More data for this Ligand-Target Pair